Back to search
FDAFDA · Food and drugs·Recall number D-1064-2016

Tazorac (tazarotene) Gel 0.05%, Rx only, packaged in a) 30g (NDC 0023-8335-03) and b) 100g (NDC 0023-8335-10) tubes, Allergan Inc, Irvine, CA 92612

Published July 13, 2016 · Recall initiated: May 10, 2016

Summary

FDA records drug Class II recall D-1064-2016, published July 13, 2016 and initiated May 10, 2016. Recalling firm: Allergan Sales, LLC; Status: Terminated; Reported quantity: 17802 units; Lot: Lot #: a) 84172, b) 84173, Exp FEB/2017. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Content Uniformity Specifications.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Allergan Sales, LLC
Distributor
Nationwide and Puerto Rico
Lot
Lot #: a) 84172, b) 84173, Exp FEB/2017
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tazorac (tazarotene) Gel 0.05%, Rx only, packaged in a) 30g (NDC 0023-8335-03) and b) 100g (NDC 0023-8335-10) tubes, Allergan Inc, Irvine, CA 92612 recalled?

Yes. FDA published recall D-1064-2016 on July 13, 2016. Reported hazard: Failed Content Uniformity Specifications.

What should I do if I have this product?

Voluntary: Firm initiated · Letter